Haploidentical HCT for Severe Aplastic Anemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04558736|
Recruitment Status : Recruiting
First Posted : September 22, 2020
Last Update Posted : September 1, 2021
This study is a prospective, single center phase II clinical trial in which patients with Severe Aplastic Anemia (SAA) ) will receive a haploidentical transplantation. The purpose of this study is to learn more about newer methods of transplanting blood forming cells donated by a family member that is not fully matched to the patient. This includes studying the effects of the chemotherapy, radiation, the transplanted cell product and additional white blood cell (lymphocyte) infusions on the patient's body, disease and overall survival. The primary objective is to assess the rate of engraftment at 30 days and overall survival (OS) and event free survival (EFS) at 1 year post-hematopoietic cell transplantation (HCT).
- To estimate the rate of engraftment at 30 days after TCR αβ+ T-cell-depleted graft infusion in patients receiving a single dose of post graft infusion cyclophosphamide.
- To estimate the overall survival and event free survival at 1-year post transplantation.
- To calculate the incidence of acute and chronic GVHD after HCT.
- To calculate the rate of secondary graft rejection at 1-year post transplantation
- To calculate the cumulative incidence of viral reactivation (CMV, EBV and adenovirus).
- To describe the immune reconstitution after TCR αβ+ T-cell-depleted graft infusion at 1 month, 3 months, 6 months, 9 months, and 1 year.
- To longitudinally assess the phenotype and epigenetic profile of T-cells in SAA patients receiving HCT for SAA.
- To assess the phenotype and epigenetic profile of T-cells in DLI administered to SAA patients post HCT.
- To longitudinally assess CD8 T cell differentiation status in SAA patients using an epigenetic atlas of human CD8 T cell differentiation.
- To examine the effector functions and proliferative capacity of CD8 T cells isolated from SAA patients before and after DLI.
- Quantify donor derived Treg cells at different time points in patients received HCT.
- Determine Treg activation status at different stages after HCT.
- Are specific features of the DLI product associated with particular immune repertoire profiles post-transplant?
- How does the diversity and functional profile of the DLI product alter the response to pathogens in the recipient?
- Do baseline features of the recipient's innate and adaptive immune cells correlate with post-transplant immune repertoires and response profiles?
|Condition or disease||Intervention/treatment||Phase|
|Aplastic Anemia Bone Marrow Failure Syndrome||Drug: Anti-Thymocyte Globulin (Rabbit) Drug: Fludarabine Drug: Cyclophosphamide Drug: Mesna Drug: G-CSF Radiation: Total Lymphoid Irradiation (TLI) Device: CliniMACS Biological: HPC, A Infusion Biological: CD45RA-depleted DLI||Phase 2|
Immunosuppressant therapy (IST) is the main treatment for SAA for patients who do not have an HLA-matched sibling donor available for transplant. But some patients with SAA do not respond to IST and some others relapse after IST. HCT using an unrelated but HLA-matched donor is the only curative option for these patients but many patients lack a suitable HLA-matched donor. St Jude is trying to increase donor options for these patients by using novel therapeutic strategies by combining two widely used of GVHD prophylaxis methods: i) selective T cell depletion and ii) use of post-transplant cyclophosphamide. This will allow expansion of the donor pool to include haploidentical donors as well as reduce the risk of GVHD. The goal of this protocol is to test whether combining these GVHD prophylaxis approaches will allow use of haploidentical donors, reduce risk of GVHD, reduce transfusion dependence and improve immune reconstitution.
For this study chemotherapy, antibodies and radiation will be given to prepare the body to receive donor cells. Participants will then be given the donor cell infusion.
Patients will receive two types of donor blood cell products - a progenitor blood cell infusion and then a donor lymphocyte infusion. Both the progenitor blood cell and the donor lymphocyte infusion will be processed in a laboratory at St. Jude using a machine called the CliniMACS™.
In this clinical trial, participants will receive a special type of progenitor blood cells (called TCRαβ- depleted blood cells) from the donor.
After the donor progenitor cells have started to grow within the body (engraftment), participants will receive a second product that contains mature immune cells. These immune cells called CD45RA-depleted lymphocytes or donor lymphocyte infusion (DLI) will help fight infections in the body after the transplant and strengthen the developing immune system.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia|
|Actual Study Start Date :||January 21, 2021|
|Estimated Primary Completion Date :||July 1, 2025|
|Estimated Study Completion Date :||July 1, 2026|
Experimental: Haploidentical HCT
To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability.
Cells for infusion are prepared using the CliniMACS System.
Drug: Anti-Thymocyte Globulin (Rabbit)
Given intravenously (IV)
Given intravenously (IV)
Other Name: Fludara Flu Dara
Given intravenously (IV)
Other Name: CYTOXAN
Given intravenously (IV)
Other Name: MESNEX
Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days, or as clinically indicated
Radiation: Total Lymphoid Irradiation (TLI)
TLI will be given at 800 cGy total dose in 4 fractions.
Other Name: TLI
The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Other Name: Cell Selection System
Biological: HPC, A Infusion
Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
Biological: CD45RA-depleted DLI
CD45RA-depleted DLI will be given at least ONE week after engraftment
- Engraftment [ Time Frame: 30 days ]Rate of patients engrafting at day 30 after TCR αβ+ T-cell-depleted graft infusion in patients receiving a single dose of post graft infusion cyclophosphamide.
- Overall and event free survival [ Time Frame: 1 year ]Rate of overall survival and event free survival at 1-year post transplantation.
- Graft vs host disease [ Time Frame: 1 year ]Incidence of acute and chronic GVHD after hematopoietic cell transplant
- Graft rejection [ Time Frame: 1 year ]Rate of secondary graft rejection at 1-year post transplantation
- Viral reactivation [ Time Frame: 1 year ]Cumulative incidence of viral reactivation post-transplant (CMV, EBV and adenovirus)
- Immune reconstitution [ Time Frame: 1 year ]We will record immune reconstitution parameters, including the order and magnitude of recovery of the different subtypes of leukocytes. Results will be summarized by descriptive statistics. The pattern of immune reconstitution will be evaluated using longitudinal approaches such as mixed effect models or generalized estimating equation (GEE) approach.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04558736
|Contact: Amr Qudeimat, MDfirstname.lastname@example.org|
|United States, Tennessee|
|St. Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105|
|Contact: Amr Qudeimat, MD 866-278-5833 email@example.com|
|Principal Investigator: Amr Qudeimat, MD|
|Principal Investigator: Akshay Sharma, MD|
|Principal Investigator:||Amr Qudeimat, MD||St. Jude Children's Research Hospital|
|Principal Investigator:||Akshay Sharma, MBBS||St. Jude Children's Research Hospital|